Arvid Carlsson

Arvid Carlsson's AcademicInfluence.com Rankings

Arvid Carlsson

Medical

#357

World Rank

#507

Historical Rank

Pharmacology

#24

World Rank

#30

Historical Rank

medical Degrees

Arvid Carlsson

Philosophy

#1773

World Rank

#3158

Historical Rank

Logic

#313

World Rank

#630

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Arvid Carlsson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Arvid Carlsson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. (2009) (2067)
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists (1957) (1196)
Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease (1990) (1112)
The current status of the dopamine hypothesis of schizophrenia. (1988) (991)
The occurrence, distribution and physiological role of catecholamines in the nervous system. (1959) (709)
Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. (2001) (699)
On the presence of 3-hydroxytyramine in brain. (1958) (630)
Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. (1969) (626)
A fluorimetric method for the determination of dopamine (3-hydroxytyramine). (1958) (613)
In‐Vivo Decarboxylation of α‐Methyl DOPA and α‐Methyl Metatyrosine (1962) (509)
Antipsychotic drugs, neurotransmitters, and schizophrenia. (1978) (458)
Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine. (1969) (428)
Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. (1966) (424)
Evidence for a receptor‐mediated feedback control of striatal tyrosine hydroxylase activity (1972) (423)
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia (2000) (398)
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. (1981) (375)
Schizophrenia: a subcortical neurotransmitter imbalance syndrome? (1990) (345)
Drugs which block the storage of 5-hydroxytryptamine and related amines (1966) (326)
Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo (1973) (313)
SEASONAL AND CIRCADIAN MONOAMINE VARIATIONS IN HUMAN BRAINS EXAMINED POST MORTEM (1980) (301)
Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in Vivo using an inhibitor of the aromatic amino acid decarboxylase (2004) (273)
Regulation of monoamine metabolism in the central nervous system. (1972) (247)
THE EFFECT OF HYPOXIA ON MONOAMINE SYNTHESIS, LEVELS AND METABOLISM IN RAT BRAIN (1973) (229)
Neurotransmitter interactions in schizophrenia—therapeutic implications (1999) (225)
Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). (1984) (217)
3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. (1981) (216)
The effect of imipramine of central 5‐hydroxytryptamine neurons (1968) (207)
Blood pressure course in patients with acute stroke and matched controls. (1986) (205)
A Paradigm Shift in Brain Research (2001) (202)
Mechanism of new antipsychotic medications: occupancy is not just antagonism. (2003) (199)
Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. (1997) (184)
Network interactions in schizophrenia — therapeutic implications (2000) (178)
(+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia (2005) (176)
Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. (1980) (163)
A regional study of sex differences in rat brain serotonin (1988) (163)
Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species (1986) (162)
Perspectives on the discovery of central monoaminergic neurotransmission. (1987) (158)
The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra (1989) (158)
Does dopamine play a role in schizophrenia? (1977) (157)
In Vivo Autoxidation of Dopamine in Guinea Pig Striatum Increases with Age (1990) (156)
The neurochemical circuitry of schizophrenia. (2006) (156)
FUNCTIONAL SIGNIFICANCE OF DRUG-INDUCED CHANGES IN BRAIN MONOAMINE LEVELS (1964) (156)
Antagonism by alpha methyltyrosine of the ethanol‐induced stimulation and euphoria in man (1973) (156)
Schizophrenia: from dopamine to glutamate and back. (2004) (154)
ROLE OF BRAIN SEROTONIN IN RESERPINE ACTION (1957) (153)
A glutamatergic deficiency model of schizophrenia (1999) (151)
Histochemical amd biochemical effects of diethyldithiocarbamate on tissue catecholamines (1966) (150)
The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice (2005) (150)
Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. (1994) (145)
Buspirone: effects on central monoaminergic transmission--possible relevance to animal experimental and clinical findings. (1982) (143)
Structural specificity for inhibition of [14C]‐5‐hydroxytryptamine uptake by cerebral slices (1970) (140)
A method for the determination of 3,4-dihydroxyphenylalanine (DOPA) in brain (2004) (137)
Central and peripheral monoaminergic membrane‐pump blockade by some addictive analgesics and antihistamines (1969) (137)
Neurotransmitter interactions in schizophrenia-therapeutic implications (1999) (135)
The 'atypicality' of antipsychotics: a concept re-examined and re-defined (2009) (135)
Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? (1986) (133)
A dopaminergic deficit hypothesis of schizophrenia: the path to discovery (2006) (133)
Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino-acids in rat brain (1978) (131)
Does dopamine have a role in schizophrenia? (1978) (122)
Effect of hypoxia on tyrosine and tryptophan hydroxylation in unanaesthetized rat brain (1973) (120)
8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity (1982) (119)
Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. (2002) (117)
MECHANISM OF AMINE TRANSPORT IN THE CELL MEMBRANES OF THE ADRENERGIC NERVES. (2009) (117)
Brain Tryptophan Hydroxylation: Dependence on Arterial Oxygen Tension (1973) (116)
The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity (2005) (116)
Potentiation of the Antidepressant Action of Clomipramine by Tryptophan (1976) (116)
Functional and biochemical aspects of catecholamine metabolism in brain under hypoxia (1975) (114)
A. PHARMACOLOGICAL DEPLETION OF CATECHOLAMINE STORES (1966) (114)
Demonstration of extraneuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine. (1969) (113)
Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems (2002) (112)
Effect of intracerebroventricularly administered somatostatin on brain monoamine turnover (1978) (106)
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. (1994) (103)
Antipsychotic Properties of the Partial Dopamine Agonist (−)-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia (1998) (99)
Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain (1985) (96)
Opiate‐receptor mediated changes in monoamine synthesis in rat brain (1978) (95)
Blockade of p-chloromethamphetamine induced 5-hydroxytryptamine depletion by chlorimipramine, chlorpheniramine and meperidine. (1971) (95)
Thirty years of dopamine research. (1993) (95)
Effects of the amphetamine group on intraneuronal brain amines in vivo and in vitro (1965) (93)
Very high blood pressure in acute stroke (1990) (90)
The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice (1999) (90)
The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study. (1993) (88)
Adrenergic mechanisms. (1969) (87)
A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity (2008) (87)
'On‐off' phenomenon in Parkinson's disease (1988) (86)
ON THE ROLE OF THE LIVER CATECHOL-O-METHYL TRANSFERASE IN THE METABOLISM OF CIRCULATING CATECHOLAMINES. (2009) (86)
Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone (1998) (86)
POTENTIATION OF ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN (1975) (86)
Neurotransmitter deficits in a non‐multi‐infarct category of vascular dementia (1989) (85)
Neurocircuitries and neurotransmitter interactions in schizophrenia (1995) (84)
Synthesis and Release of Dopamine in Rat Brain: Comparison Between Substantia Nigra Pars Compacta, Pars Reticulata, and Striatum (1989) (83)
Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine Levels in human basal ganglia (2005) (81)
Biochemical and pharmacological aspects of Parkinsonism. (1972) (81)
Suppression of ethanol-induced locomotor stimulation by GABA-like drugs (1976) (81)
Inhibition of 3H‐metaraminol uptake by antidepressive and related agents (1965) (80)
N-Alkylated 2-aminotetralins: central dopamine-receptor stimulating activity. (1979) (80)
3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity. (1981) (80)
Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice (2007) (78)
Oral L-dopa treatment of parkinsonism. (2009) (77)
5-HYDROXYTRYPTAMINE RELEASE BY NERVE STIMULATION OF THE SPINAL CORD. (1964) (76)
Effect of a transverse cerebral hemisection on 5-hydroxytryptamine metabolism in the rat brain (2004) (74)
MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. (1997) (73)
Inhibition of ethanol-induced excitation in mice and rats by α-methyl-p-tyrosine (2004) (72)
Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. (1985) (71)
Rat brain serotonin: Biochemical and functional evidence for a sex difference (2005) (69)
Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups. (1987) (68)
Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease. (1990) (66)
Effects of (−)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization (2008) (65)
Influence of transient ischemia on monoamine metabolism in the rat brain during nitrous oxide and phenobarbitone anaesthesia (1978) (63)
A behavioural pattern analysis of hypoglutamatergic mice – effects of four different antipsychotic agents (2001) (62)
Catecholamines and behavior. (1977) (62)
Marked locomotor stimulation in monoamine-depleted mice following treatment with atropine in combination with clonidine (1989) (62)
Release of serotonin from blood platelets by reserpine in vitro. (1957) (60)
8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists. (1984) (59)
Effects of antidepressant agents on the synthesis of brain monoamines (2005) (59)
NOBEL LECTURE: A Half-Century of Neurotransmitter Research: Impact on Neurology and Psychiatry (2001) (58)
The Monoamine Stabilizer (-)-OSU6162 Attenuates Voluntary Ethanol Intake and Ethanol-Induced Dopamine Output in Nucleus Accumbens (2012) (57)
Monoamine oxidase -A and -B activity in the rat brain after hemitransection. (1980) (57)
Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. (1983) (57)
Effects of gonadectomy and hormone replacement on brain monoamine synthesis in male rats (1979) (56)
Beta-adrenergic control of brain uptake of large neutral amino acids. (1988) (56)
Biochemical aspects of dopamine agonists. (1975) (56)
A METHOD FOR THE FLUORIMETRIC DETERMINATION OF 3-METHOXYTYRAMINE IN TISSUES AND THE OCCURRENCE OF THIS AMINE IN BRAIN. (1964) (55)
Acute effects of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine on dopamine metabolism in mouse and rat striatum (1985) (54)
Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique. (1976) (54)
5-Hydroxytryptamine of the spinal cord normally and after transection (1963) (53)
Placebo-controlled cross-over study of the monoaminergic stabiliser (−)-OSU6162 in mental fatigue following stroke or traumatic brain injury (2012) (53)
Glycine and D-serine decrease MK-801-induced hyperactivity in mice (2005) (53)
An Improved HPLC‐Electrochemical Detection Method for Measuring Brain Levels of 5‐S‐Cysteinyldopamine, 5‐S‐Cysteinyl‐3,4‐Dihydroxyphenylalanine, and 5‐S‐Cysteinyl‐3,4‐Dihydroxyphenylacetic Acid (1990) (52)
Turnover of Dopamine and Dopamine Metabolites in Rat Brain: Comparison Between Striatum and Substantia Nigra (1987) (51)
Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice (2005) (50)
Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor‐α and interleukin‐12 in asymptomatic individuals in response to live spirochetes (2005) (50)
Effects of amphetamine, tyramine, and protriptyline on reserpine‐resistant amine‐concentrating mechanisms of adrenergic nerves (1966) (49)
Evidence for dopamine release and metabolism beyond the control of nerve impulses and dopamine receptors in rat substantia nigra (1985) (49)
Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release (2005) (49)
Dopamine receptor agonists: Intrinsic activity vs. state of receptor (2005) (49)
PHYSIOLOGICAL AND PHARMACOLOGICAL RELEASE OF MONOAMINES IN THE CENTRAL NERVOUS SYSTEM (1966) (48)
The effect of intracerebroventricularly administered GABA on brain monoamine metabolism (1977) (48)
Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. (1999) (47)
Metatyrosine as a tool for selective protection of catecholamine stores against reserpine. (1967) (47)
(+)-AJ 76 and (+)-UH 232: Central stimulants acting as preferential dopamine autoreceptor antagonists (1986) (47)
5‐HT reuptake inhibitors plus tryptophan in endogenous depression (1981) (46)
Effect of a new series of bicyclic compounds with potential thymoleptic properties on the reserpine‐resistant uptake mechanism of central and peripheral monoamine neurones in vivo and in vitro (1969) (46)
Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. (1985) (46)
(−)-Pindolol stereospecifically inhibits rat brain serotonin (5-HT) synthesis (1985) (45)
Region-selective activation of brain monoamine synthesis by sexual activity in the male rat. (1987) (45)
The dopaminergic stabilizers (−)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats (2005) (45)
On the neuronal circuitries and neurotransmitters involved in the control of locomotor activity. (1993) (43)
Nicotine treatment of obsessive–compulsive disorder (2004) (43)
Decrease in plasma amino acids in rat after acute administration of ethanol (1980) (43)
Effects of the substituted (S)‐3‐phenylpiperidine (−)‐OSU6162 on PET measurements in subhuman primates: Evidence for tone‐dependent normalization of striatal dopaminergic activity (1998) (43)
A Half‐Century of Neurotransmitter Research: Impact on Neurology and Psychiatry (Nobel Lecture) (2001) (42)
Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. (1985) (41)
The effect of β-alanine on motor behaviour, body temperature and cerebral monoamine metabolism in rat (2005) (41)
The effect of (+)‐amphetamine on various central and peripheral catecholamine‐containing neurones (1966) (41)
Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain (1977) (41)
A half-century of neurotransmitter research: impact on neurology and psychiatry (2002) (41)
Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity II. Theoretical considerations (2005) (40)
Vitamin C Deficiency Facilitates 5‐S‐Cysteinyldopamine Formation in Guinea Pig Striatum (1991) (40)
Monoamine metabolism during bicuculline-induced epileptic seizures in the rat (1978) (40)
ANTIPSYCHOTIC DRUGS AND CATECHOL- AMINE SYNAPSES (1974) (40)
A method for the determination of normetanephrine in brain. (1962) (40)
In-vivo measurements of tryptophan and tyrosine hydroxylase activities in mouse brain (2005) (40)
The Ca++-antagonist nimodipine decreases and the Ca++-agonist Bay K 8644 increases catecholamine synthesis in mouse brain (1987) (40)
Antipsychotic drugs and catecholamine synapses. (1974) (39)
Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers. (1983) (39)
Failure of dopamine to accumulate in central noradrenaline neurons after depletion with diethyldithiocarbamate (1967) (39)
Distribution of Dopamine in the rat cerebral cortex (2005) (38)
Lack of functional evidence for the involvement of sigma opiate receptors in the actions of the 3-PPP enantiomers on central dopaminergic systems: discrepancies between in vitro and in vivo observations. (1985) (38)
Effect of ethanol on the metabolism of brain catecholamines (2004) (38)
Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia (1998) (38)
I. In vivo evidence for partial agonist effects of (−)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors (2011) (37)
Early psychopharmacology and the rise of modern brain research (1990) (37)
Suppression by dopamine-agonists of the ethanol-induced stimulation of locomotor activity and brain dopamine synthesis (2004) (37)
Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity (2005) (37)
NORADRENALINE RELEASE BY NERVE STIMULATION OF THE SPINAL CORD. (1965) (37)
Anticonflict effects of low doses of the dopamine agonist apomorphine in the rat (1986) (37)
Agonist-antagonist interaction on dopamine receptors in brain, as reflected in the rates of tyrosine and tryptophan hydroxylation (2005) (36)
The Effect of Pronounced Hypoglycemia on Monoamine Metabolism in Rat Brain (1979) (36)
Multiple biochemical deficits in both gray and white matter of Alzheimer brains (1986) (36)
Temporary and partial antagonism by l-DOPA of reserpine-induced suppression of a conditioned avoidance response (1963) (35)
HISTOCHEMICAL AND BIOCHEMICAL DETECTION OF MONOAMINE RELEASE FROM BRAIN NEURONS. (1965) (35)
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. (1993) (34)
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity. (1982) (34)
Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232 (1992) (34)
RESERPINE-RESISTENT UPTAKE MECHANISMS OF NORADRENALINE IN TISSUES. (1963) (34)
The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition (2004) (34)
Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans. (2001) (34)
Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour (2005) (34)
(+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis. (1984) (34)
(+)-cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist. (1987) (34)
II. In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors (2011) (34)
Accumulation of 5‐hydroxytryptophan in mouse brain after decarboxylase inhibition (1970) (33)
A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment (2005) (33)
Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity. (1981) (32)
The effect of L-tryptophan and some psychotropic drugs on the formation of 5-hydroxytryptophan in the mouse brain in vivo (2005) (32)
Dopa reversal of hypoxia‐induced disruption of the conditioned avoidance response (1973) (32)
Release of 3H-Metaraminol by Different Mechanisms1 (1966) (32)
SOME FACTORS INFLUENCING THE RELEASE OF NORADRENALINE INTO THE BLOOD FOLLOWING SYMPATHETIC STIMULATION. (1964) (31)
N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: novel central 5-hydroxytryptamine receptor agonists. (1988) (31)
THE IMPACT OF CATECHOLAMINE RESEARCH ON MEDICAL SCIENCE AND PRACTICE (1979) (31)
Effect of hypercapnia and hypocapnia on tryptophan and tyrosine hydroxylation in rat brain. (1977) (30)
Decrease in plasma amino acids in man after an acute dose of ethanol. (1983) (30)
Alteration of central catecholamine metabolism following acute administration of ethanol (1978) (29)
The effects of the monoamine stabilizer (-)-OSU6162 on craving in alcohol dependent individuals: A human laboratory study (2015) (29)
Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: Potential treatment of extrapyramidal side effects (1993) (28)
On the mechanism of 5‐hydroxytryptamine release by thymoleptics (1969) (28)
The contribution of drug research to investigating the nature of endogenous depression. (1976) (28)
Glutamatergic neurons projecting to the nucleus accumbens can affect motor functions in opposite directions depending on the dopaminergic tone (1994) (28)
Effects of the substituted (S)-3-phenylpiperidine (−)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains (1999) (28)
Ethanol‐induced increase in the penetration of exogenously administered L‐dopa through the blood‐brain barrier (1979) (27)
The role of intraneuronal amine levels in the feedback control of dopamine, noradrenaline and 5-hydroxytryptamine synthesis in rat brain (2005) (27)
Age-dependent changes in central dopaminergic and other monoaminergic systems. (1978) (27)
Resolved cis- and trans-2-amino-5-methoxy-1-methyltetralins: central dopamine receptor agonists and antagonists. (1987) (27)
Basic concepts underlying recent developments in the field of Parkinson's disease. (1971) (27)
Dopaminergic autoreceptors: background and implications. (1977) (26)
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model. (1990) (26)
Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. (2003) (26)
Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice (2005) (26)
Hypothalamic monoamines and neuropeptides in dementia (1991) (26)
Effect of baclofen on cerebrospinal-fluid levels of 5-hydroxyindoleacetic acid and homovanillic acid. (1977) (26)
The adrenal dopamine as an indicator of adrenomedullary hormone biosynthesis (2004) (26)
Adrenergic influence on rat plasma concentrations of tyrosine and tryptophan. (1982) (26)
A new centrally acting DA-receptor agonist with selectivity for autoreceptors. (1980) (25)
Some aspects of dopamine in the basal ganglia. (1976) (25)
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors. (1987) (25)
The interference of tetrabenazine, benzquinamide and prenylamine with the action of reserpine. (2009) (25)
Letters to the Editor: In vitro release of endogenous histamine, together with noradrenaline and 5‐hydroxytryptamine, from slices of mouse cerebral hemispheres (1972) (25)
Effect of Reserpine on Monoamine Synthesis and on Apparent Dopaminergic Receptor Sensitivity in Rat Brain (1978) (25)
In vivo evidence for a greater brain tryptophan hydroxylase capacity in female than in male rats (1988) (24)
Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity. (1995) (23)
Pharmacologic properties of (−)-3PPP (preclamol) in man (2005) (23)
Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors (1991) (23)
Correction: a note on the discovery of selective serotonin reuptake inhibitors. (1997) (23)
Tolerability and efficacy of the monoaminergic stabilizer (−)-OSU6162 (PNU-96391A) in Huntington’s disease: a double-blind cross-over study (2014) (23)
The effect of taurine on motor behaviour, body temperature and monoamine metabolism in rat brain (1978) (23)
Stimulating and inhibitory effects of the dopamine “stabilizer” (−)-OSU6162 on dopamine D2 receptor function in vitro (2007) (22)
Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway? (1983) (22)
Interhemispheric transfer in high‐functioning children and adolescents with autism spectrum disorders: a controlled pilot study (2004) (22)
Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioral studies. (1982) (22)
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo. (1993) (22)
The occurrence and functional significance of dopamine in some peripheral adrenergic nerves of the rat (2004) (22)
The Dopamine Hypothesis of Schizophrenia 20 Years Later (1987) (22)
Interhemispheric transfer in high-functioning children and adolescents with autism spectrum disorders: a controlled pilot study. (2004) (22)
On the disulfiram-like effect of coprine, the pharmacologically active principle of Coprinus atramentarius. (2009) (21)
Potentiation of phenothiazines byα-methyltyrosine in treatment of chronic schizophrenia (2005) (21)
The Dopamine Stabilizer (−)-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects (2015) (21)
Some aspects of dopamine in the central nervous system. (1974) (21)
Pharmacology of synaptic monoamine transmission. (1969) (21)
In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH 23390 (2005) (21)
Influence of GABA and GABA-like drugs on monoaminergic mechanisms. (1977) (20)
Brain and heart catecholamine levels after l-Dopa administration in reserpine treated mice: Correlations with a conditioned avoidance response (1964) (20)
Studies on the acute and long-term changes in dopamine and noradrenaline metabolism in mouse brain following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (1988) (20)
The effect of intraperitoneally administered GABA on brain monoamine metabolism (1977) (20)
Rapid release of 3H‐metaraminol induced by combined treatment with protriptyline and reserpine (1965) (20)
Acute dopaminergic influence on plasma adrenaline levels in the rat. (1995) (20)
The neurogenic short-term control of catecholamine synthesis and release in the sympatho-adrenal systems, as reflected in the levels of endogenous dopamine and β-hydroxylated catecholamines (1973) (19)
Neurotransmitter changes in the aging brain. (1985) (19)
Adaptive properties and heterogeneity of dopamine D2 receptors – Pharmacological implications (2008) (19)
Measurements of monoamine synthesis and turnover with special reference to 5-hydroxytryptamine. (1974) (19)
Capsaicin-sensitive vasodilatatory mechanisms in the rat substantia nigra and striatum (2005) (19)
REDUCED ADRENAL AMINE SYNTHESIS IN SPONTANEOUSLY HYPERTENSIVE RATS AFTER LONG‐TERM TREATMENT WITH PROPRANOLOL (1977) (19)
Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice (1991) (19)
An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system (1985) (18)
Dopamine receptor-mediated hypothermia induced in rats by (+)-, but not by (-)-3-PPP. (1985) (18)
Catecholamine synthesis in rat brain after axotomy: Interaction between apomorphine and haloperidol (1977) (18)
Postsynaptic dopamine (DA) receptor stimulator properties of the putative DA autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D-1 agonist SK&F 38393 (2004) (18)
The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin (2005) (18)
Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice (2005) (18)
C3-methylated 5-hydroxy-2-(dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation. (1987) (18)
8-HYDROXY-2-(DIPROPYLAMINO)TETRALIN, A NEW CENTRALLY ACTING 5-HYDROXYTRYPTAMINE RECEPTOR AGONIST (1982) (18)
Basic actions of psychoactive drugs. (1967) (18)
Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig (1991) (18)
Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography. (1997) (18)
Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes. (1995) (17)
Different mechanisms of drug-induced release of noradrenaline and its congeners alpha-methylnoradrenaline and metaraminol. (1968) (17)
Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. (1988) (17)
Preclamol and parkinsonian fluctuations. (1993) (17)
Short-term control of tyrosine hydroxylase. (1974) (17)
Brain monoamine abnormalities in the two types of Creutzfeldt‐Jakob disease (1982) (17)
Pivaloyl esters of N,N-dialkylated dopamine congeners. Central dopamine-receptor stimulating activity. (1978) (17)
The influence of nerve-impulse flow on the synthesis and metabolism of 5-hydroxytryptamine in the central nervous system. (1972) (17)
Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity. (1997) (16)
Postmortal accumulation of 3-methoxytyramine in brain (2004) (16)
Substituted metatyramines as brain monoamine depletors. (1970) (16)
Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo. (1994) (16)
The accumulation of [3H]noradrenaline in the adrenergic nerve fibres of reserpine‐treated mice (1967) (16)
(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists. (1993) (16)
Antagonism of ethanol's central stimulation in mice by small doses of catecholamine-receptor agonists (1977) (15)
Neurotransmitters in Old Age and Dementia (1986) (15)
Current theories on the mode of action of antidepressant drugs. (1984) (15)
Pharmacology of the sympathetic nervous system (1966) (15)
Structure-activity relationships for release of 14C-octopamine from adrenergic nerves by phenylethylamines. (2009) (15)
UPTAKE, STORAGE AND RELEASE OF H3-α-METHYLNOREPINEPHRINE (1967) (15)
Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue (2005) (15)
(+)-UH 232 and (+)-UH 242: Novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors (2005) (14)
The effect of CO2 on monoamine metabolism in rat brain (1977) (14)
Further studies on the mechanism of antipsychotic action: Potentiation by α-methyltyrosine of thioridazine effects in chronic schizophrenics (2005) (14)
Increased dopamine release by the autoreceptor antagonist (+)-AJ 76 is Ca2(+)-dependent. (1990) (14)
N-ALKYLATED 2-AMINOTETRALINS: CENTRAL DOPAMINE-RECEPTOR STIMULATING ACTIVITY (1980) (14)
In-vivo decarboxylation of alpha-methyl DOPA and alpha-methyl metatyrosine. (1962) (14)
Some current problems related to the mode of action of antidepressant drugs (1981) (14)
The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats. (1987) (14)
On the -hydroxylation of ()-a-methyldopamine in vivo (1968) (14)
Anxiolytic-like action of the 3-PPP enantiomers in the Vogel conflict paradigm (2004) (13)
Acute changes in dopamine levels in rat adrenal glands after administration of dopamine receptor agonists and antagonists. (1990) (13)
Development of new pharmacological approaches in Parkinson's disease. (1987) (13)
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists. (1994) (13)
Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control (2005) (13)
C1- and C3-methyl-substituted derivatives of 7-hydroxy-2-(di-n-propylamino)tetralin: activities at central dopamine receptors. (1987) (13)
Synthesis and pharmacology of the enantiomers of cis-7-hydroxy-3-methyl-2-(dipropylamino)tetralin. (1990) (13)
Injection of capsaicin into the nucleus raphe dorsalis elicits heat loss in the rat (1987) (12)
Antagonism by baclophen of thed-amphetamine-induced disruption of a successive discrimination in the rat (2005) (12)
Towards a New Understanding of Dopamine Receptors (1995) (12)
Effect of intraperitoneally administered GABA on the locomotor activity of mice (1978) (12)
Effects of capsaicin on central monoaminergic mechanisms in the rat (2005) (12)
In vivo effects of the Ca2+-antagonist nimodipine on dopamine metabolism in mouse brain (2005) (12)
Effect of Drugs on Amine Uptake Mechanisms in the Brain (1970) (12)
On the roles of dopamine D-1 vs. D-2 receptors for the hyperactivity response elicited by MK-801 (2005) (12)
Selective protection of 5‐hydroxytryptamine stores against the action of reserpine by treatment with 5‐hydroxytryptophan (1967) (12)
Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats (2011) (12)
A randomised controlled trial of the monoaminergic stabiliser (−)-OSU6162 in treatment of myalgic encephalomyelitis/chronic fatigue syndrome (2017) (11)
The activities of monoamine oxidase-A and-B, succinate dehydrogenase and acid phosphatase in the rat brain after hemitransection (1981) (11)
CORRELATION BETWEEN CONCENTRATION OF DOPA IN PLASMA AND THE “ON‐OFF” PHENOMENON (1984) (11)
Biogenic Amines and Related Enzymes in Normal Aging, Senile Dementia and Chronic Alcoholism (1981) (11)
Potentiation of neuroleptics by catecholamine inhibitors. (1973) (11)
Decarboxylation of orally administered l-dopa in the human digestive tract (2004) (11)
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics. (1986) (11)
The effect of the enantiomers of 3-PPP on conditioned avoidance responding in the rat (2004) (11)
NOVEL DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS WITH PREFERENTIAL ACTION ON AUTORECEPTORS (1985) (10)
On the mode of action of diazepam on brain catecholamine metabolism (1978) (10)
The Effects of 1‐Methyl‐4‐phenylpyridinium Ion (MPP+) on the Efflux and Metabolism of Endogenous Dopamine in Rat Striatal Slices (1988) (10)
C1-Methylated 5-hydroxy-2-(dipropylamino)tetralins: central dopamine-receptor stimulating activity. (1984) (10)
In vivo activity of tyrosine hydroxylase in rat adrenal glands following administration of quinpirole and dopamine. (1995) (10)
INTERACTION BETWEEN DOPAMINERGIC AND SEROTONERGIC SYSTEMS (1992) (10)
Pharmacological properties of presynaptic dopamine receptor agonists. (1985) (10)
RESOLVED 3-(3-HYDROXYPHENYL)-N-N-PROPYLPIPERIDINE AND ITS ANALOGS: CENTRAL DOPAMINE RECEPTOR ACTIVITY (1985) (10)
Effect of pentobarbitone and diethyl ether on the synthesis of monoamines in rat brain (2004) (10)
Mechanism of release of α-methylated noradrenaline analogues by monoamine oxidase inhibitors (1968) (10)
Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (9)
Synthesis and biological activity of C-5 modified derivatives of (+)-AJ76 and (+)-UH232: Increased dopamine D3 receptor preference and improved pharmacokinetic properties (1994) (9)
Resolved 6,7,8,9-tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: central dopamine and serotonin receptor stimulating properties. (1989) (9)
Recent studies on the mode of action of antidepressive drugs (2004) (9)
Isoprenaline increases brain concentrations of administered l-dopa and l-tryptophan in the rat (2004) (9)
Effect of desmethylimipramine, protriptyline and (+)-amphetamine on fluorescence of central adrenergic neurons of rats pretreated with alpha-methyl-DOPA and tetrabenazine or reserpine. (1967) (9)
“On-off” phenomenon in Parkinson's disease: Correlation to the concentration of dopa in plasma (2005) (9)
Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias (2005) (9)
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin. (1988) (9)
Recovery of dopamine in peripheral adrenergic nerves after reserpine treatment (2004) (8)
Synthesis and biological activity of cis-(3aR)-(-)-2,3,3a,4,5,9b-hexahydro- 3-propyl-1H-benz[e]indole-9-carboxamide: a potent and selective 5-HT1A receptor agonist with good oral availability. (1993) (8)
RESOLVED MONOPHENOLIC 2-AMINOTETRALINS AND 1,2,3,4,4A,5,6,10B-OCTAHYDROBENZO(F)QUINOLINES: STRUCTURAL AND STEREOCHEMICAL CONSIDERATIONS FOR CENTRALLY ACTING PRE- AND POSTSYNAPTIC DOPAMINE-RECEPTOR AGONISTS (1985) (8)
CHILDREN WITH AUTISM GROW UP Use of the DISCO ( Diagnostic Interview for Social and COmmunication disorders ) in population cohorts (2007) (8)
Central dopaminergic properties of HW-165 and its enantiomers; Trans-octahydrobenzo(f)quinoline congeners of 3-PPP (1986) (8)
5-, 6-, 7- and 8-amino-2-(N,N-di-n-propylamino)-1,2,3,4-tetrahydronaphthalenes: centrally acting DA and 5-HT1A agonists (1993) (8)
In vivo displacement by 3-PPP enantiomers of N,N-dipropyl-5,6-ADTN from dopamine receptor-binding sites in rat striatum (2005) (7)
Antipsychotic treatment withα-methyltyrosine in combination with thioridazine: Prolactin response and interaction with dopaminergic precursor pools (2005) (7)
The effects of the dopamine stabilizer (−)-OSU6162 on aggressive and sexual behavior in rodents (2016) (7)
Effect of acute transection on the synthesis and turnover of 5-HT in the rat spinal cord (2004) (7)
Resolved cis-10-hydroxy-4-n-propyl-1,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline : central serotonin stimulating properties. (1987) (7)
Psychopharmacology: Basic Aspects (1980) (7)
Sexually differentiated actions of 3-PPP enantiomers on prolactin secretion (1986) (7)
Ethanol-induced increase in brain concentrations of administered neutral amino acids (1980) (7)
Recent observations on new potential and established antidepressant drugs. (1982) (7)
Effect of diazepam on cerebral monoamine synthesis during hypoxia and hypercapnia in the rat. (1982) (7)
Birth of neuropsychopharmacology– impact on brain research (1999) (7)
Birth of Dopamine: A Cinderella Saga (2002) (6)
1H magnetic resonance spectroscopy evidence for occipital involvement in treatment-naive paediatric obsessive–compulsive disorder (2016) (6)
Beta-adrenergic influence on brain concentrations of monoamine precursors. (1984) (6)
The inhibition of rat brain monoamine oxidase-B by J-508 (N-methyl-N-propargyl-(1-indanyl)-ammonium hydrochloride), and its use for the titration of this enzyme form. (1979) (6)
Neurochemical Changes in Brains from Patients with Vascular Dementia (1991) (6)
The putatively selective dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 stimulate prolactin release in rats. (1986) (6)
A faulty negative feedback control underlies the schizophrenic syndrome? (1991) (6)
Modification of sympathetic function. Pharmacological depletion of catecholamine stores. (1966) (6)
Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice (2005) (6)
Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (NMPTP) in mouse brain (2005) (6)
Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. (1996) (6)
A homologous series of N-alkylated cis-(+)-(1 S, 2 R)-5-methoxy-1-methyl-2-aminotetralins: Central dopamine receptor antagonists showing profiles ranging from classical antagonism to selectivity for autoreceptors (2005) (6)
Effects of mild stress on adrenal and heart catecholamines in male and female rats (2005) (5)
Dual action of methadone on 5-HT synthesis and metabolism (1979) (5)
Neurotensin and its amide analogue [Gln4]-neurotensin: effects on brain monoamine turnover (1978) (5)
Attempts to measure endogenous levels of dopa and 5-hydroxytryptophan in rat brain (2005) (5)
Progress in Dopamine Research Schizophrenia : A Guide for Physicians (2004) (5)
Evidence for an increased catecholamine synthesis in rat adrenal glands following stimulation of peripheral dopamine receptors (2005) (5)
Peptide neurotransmitters--redundant vestiges? (1988) (5)
Open study with (−)‐OSU6162 in multiple sclerosis‐related fatigue (2018) (5)
Rapid communication Stimulating and inhibitory effects of the dopamine ''stabilizer'' (2)-OSU6162 on dopamine D2 receptor function in vitro (2007) (5)
Sub-chronic administration of (−)-3-PPP and central dopamine receptor sensitivity changes (2005) (5)
Synergistic interactions between the NMDA antagonist dizocilpine and the preferential dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 with regard to locomotor stimulation in monoamine-depleted mice (2005) (5)
Effect of synthetic substance P on monoaminergic mechanisms in brain (2005) (5)
Potentiation by neuroleptic agents of the inhibitory action of intraperitoneally administered GABA on the locomotor activity of mice (1978) (5)
8-HYDROXY-2-(ALKYLAMINO)TETRALINS AND RELATED COMPOUNDS AS CENTRAL 5-HYDROXYTRYPTAMINE RECEPTOR AGONISTS (1984) (5)
Effects of repeated administration of the preferential dopamine autoreceptor antagonist, (+)-AJ76, on locomotor activity and brain DA metabolism in the rat. (1991) (5)
Dopamine receptors, controlling dopamine levels in rat adrenal glands — comparison with central dopaminergic autoreceptors (2005) (5)
On the Biochemistry and Possible Functions of Dopamine and Noradrenaline in Brain (2008) (5)
Effect of Peptides on Brain Monoamines and on Gross Behaviour (1979) (4)
Monoamine oxidase-A and -B activities in the brain stem of schizophrenics and non-schizophrenic psychotics (2005) (4)
Studies on the neurogenic short-term control of adrenomedullary hormone synthesis (2005) (4)
Pharmacological Approach to Schizophrenia (1985) (4)
Studies on the synthesis and subcellular distribution of dopamine in the rat adrenal medulla (1975) (4)
Mediodespidine, hypotensive reserpoid without sedative effect. II. Effect on monoamine levels in mouse organs. (1965) (4)
Artificial blood vessels (2009) (4)
The search for selective dopaminergic autoreceptor agonists. (1983) (4)
POTENTIATION OF THE EFFECT OF ANTIDEPRESSANT DRUGS BY TRYPTOPHAN (1980) (4)
Effects of hypophysectomy, adrenalectomy and (−)-propranolol on ethanol-induced decrease in plasma amino acids (1981) (4)
Effects of MPP+ on catecholamine levels in adrenal glands and heart of rats (1994) (4)
A behavioural study of the changes in the central nervous system of mice after subchronic treatment with the selective dopamine autoreceptor agonist 3-PPP (dl-3-[3-hydroxyphenyl]-N-n-propylpiperidine) (2005) (4)
Dopamine-Receptor Subtypes in Neurological and Psychiatric Disease: Introduction (1995) (4)
The chemical structure of U99194A. (1995) (4)
Network interactions in schizophrenia — therapeutic implications 1 (2000) (4)
6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. (1992) (4)
Antipsychotic Drugs as Tools for Etiological Research (1990) (3)
[Mode of action of tricyclic antidepressants]. (1973) (3)
Indirect central 5-hydroxytryptaminergic actions of methoxy substituted 2-aminotetralin derivatives. (1986) (3)
The influence of nerve-impulse flow on the synthesis and metabolism of hydroxytryptamine. (1972) (3)
Presynaptic Dopaminergic Autoreceptors as Targets for Drugs (1991) (3)
Substance P: structural requirements for the activation of brain catecholamine synthesis and locomotor activity in rats. (1983) (3)
Formation of dopamine from 3-methoxytyrosine (2004) (3)
Effect of acute ethanol on the distribution of amino acids (1980) (3)
BETA-HYDROXYLATION OF TYRAMINE IN VIVO. (1963) (3)
Vascular depression : new light on an established idea ? (2000) (3)
Schizophrenia: a neurotransmitter imbalance syndrome? (1990) (3)
Release of 3H-metaraminol by different mechanisms. (1966) (3)
The putatively antipsychotic agent amperozide produces behavioural stimulation in the rat (1989) (3)
Neurotransmitter dysfunctions in schizophrenia (1994) (3)
Neurohumoral transmission and neuropsychiatric disorders. (1967) (3)
The Neurobiology of Slow Synaptic Transmission (2001) (3)
Mechanism of release of alpha-methylated noradrenaline analogues by monoamine oxidase inhibitors. (1968) (3)
FUTURE DIRECTIONS IN ANTIPSYCHOTIC DRUG RESEARCH (1992) (2)
Nerves as Chemical Messengers (2005) (2)
C1-METHYLATED 5-HYDROXY-2-(DIPROPYLAMINO)TETRALINS: CENTRAL DOPAMINE-RECEPTOR STIMULATING ACTIVITY (1985) (2)
FAILURE OF RESERPINE TO DEPLETE NORADRENALINE NEURONS OF ALPHA-METHYLNORADRENALINE FORMED FROM ALPHA-METHYL DOPA. (1965) (2)
Historical aspects and future directions (2003) (2)
Failure of Reserpine to Deplete Noradrenaline Neurons of α‐Methylnoradrenaline Formed from α‐Methyl DOPA (2009) (2)
(S)- and (R)-8-(Di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz(e)indole- 1-carbaldehyde : A New Class of Orally Active 5HT1A-Receptor Agonists. (1994) (2)
Structure‐Activity Relationships in the 8‐Amino‐6,7,8,9‐tetrahydro‐3H‐ benz(e)indole Ring System. Part 1. Effects of Substituents in the Aromatic System on Serotonin and Dopamine Receptor Subtypes. (1995) (2)
Reply to commentaries on ?the current status of the dopamine hypothesis of schizophrenia?*1 (1988) (2)
PIVALOYL ESTERS OF N,N‐DIALKYLATED DOPAMINE CONGENERS. CENTRAL DOPAMINE‐RECEPTOR STIMULATING ACTIVITY (1979) (2)
C3‐Methylated 5‐Hydroxy‐2‐(dipropylamino)tetralins: Conformational and Steric Parameters of Importance for Central Dopamine Receptor Activation. (1987) (2)
Differential locomotor interactions between dopamine D1/D2 receptor agonists and NMDA antagonists (1993) (2)
Photodynamic therapy for treatment of Acne Vulgaris in clinical studies ; dose response and mode of action (2009) (2)
Intra-articular steroids--an alternative to knee synovectomy in rheumatoid arthritis? (1984) (2)
Opposite effects of naloxone on substance P-induced changes in brain dopa synthesis and in locomotor activity in rats (2005) (2)
Current views on the mode of action of antidepressant drugs (1986) (2)
3-PPP Enantiomers and Brain Sigma Opiate Sites: Discrepancies between in vitro and in vivo Observations (1986) (2)
In vivo dopamine (DA) receptor binding and behavioural effects of the putative DA autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 in rats with a unilateral nigral 6-OH-DA lesion (2004) (2)
A behavioral study of the changes in the CNS of mice after subchronic treatment with the dopamine autoreceptor agonist 3-PPP. (1982) (2)
MONOPHENOLIC OCTAHYDROBENZO(F)QUINOLINES: CENTRAL DOPAMINE- AND SEROTONIN-RECEPTOR STIMULATING ACTIVITY (1983) (2)
[On the problem of the mechanism of action of some psychopharmaca]. (1960) (2)
Effects of enkephalins and two enzyme resistant analogues on monoamine synthesis and metabolism in rat brain (2004) (2)
[Cerebral monoamines]. (1966) (2)
Brain Neurotransmitters in Normal Aging (1985) (2)
Signal Transduction In The Nervous System (2019) (2)
Uptake, storage and release of H3-alpha-methyl norepinephrine. (1967) (2)
THE SEARCH FOR NEW MONOAMINERGIC RECEPTOR AGONISTS (1982) (2)
Monoamine concentrations in the human brain. A comparison between two methods of tissue handling (2005) (2)
Experiments with Radiocalcium on the Interrelationships between Vitamin D and Dietary Caleium and Phosphorus. (2009) (2)
Rat brain concentration of administered amino acids: Dependence on time of day for administration (2005) (1)
Perspectives on Dopamine as a Regulator of Brain Function (1990) (1)
Brain monoamines in cases with Down's syndrome with and without dementia (1982) (1)
EFFECTS OF PEPTIDES ON BRAIN MONOAMINE METABOLISM AND ON GROSS BEHAVIOUR IN RATS (1979) (1)
PL-3 The dopamine and glutamate hypotheses of schizophrenia — therapeutic implications of an integrated view (1995) (1)
Molecular mechanisms behind the liver-induced acceptance of renal grafts in highly sensitized patients (2009) (1)
Effects of pentobarbital and diazepam on rat plasma amino acid patterns (1981) (1)
Future Diagnostic and Therapeutic Strategies: A Realistic Forecast (1985) (1)
272 Discussion of the previous paper. the role of dopamine in the central nervous system (1961) (1)
A Historical Note on the Development of Zimelidine, the First Selective Serotonin Reuptake Inhibitor (1996) (1)
OSU6182 a representative from a unique class of functional modulators of dopaminergic systems (1997) (1)
Influence of GBR 12909 and d-amphetamine on indices of catecholamine synthesis and release in rat adrenal glands (1994) (1)
D-1 Agonist Co-treatment Uncovers Postsynaptic Dopamine (DA) Receptor Stimulatory Properties of B-HT 920, a Putative DA (D-2) Autoreceptor-selective Agonist (1988) (1)
Fifteen years of continued research in psychopharmacology. (1992) (1)
L-2-1 Recent advances in the therapeutics of schizophrenia: Is dopamine still relevant? (1996) (1)
Pre- and postsynaptic mechanisms in haloperidol-induced sensitization to dopaminergic agonists. (1980) (1)
β‐Hydroxylation of Tyramine in Vivo (2009) (1)
Recent advances in the treatment of depression. Proceedings of an international symposium, Corfu, Greece, April 16--18, 1980. (1981) (1)
Current Topics in Extrapyramidal Disorders (1980) (1)
Diagnostic aspects of lichen sclerosus and skin cancer studied with laser scanning microscopy (2020) (1)
On the catechol amine levels in blood plasma after stimulation of the sympathoadrenal system (1958) (1)
Neuropsychopharmacology: Gazing into the crystal ball (1988) (1)
Role of Brain Monoamines and Other Neurotransmitters in Normal and Pathological Aging (1990) (1)
Synthesis and pharmacology of the enantiomers of cis-7-hydroxy-3-methyl-2-(dipropylamino)tetralin [Erratum to document cited in CA113(21):190865h] (1991) (1)
S-2-1 Stabilizing action of partial dopamine receptor agonists in psychosis (1996) (1)
Effects of ethanol on plasma amino acids mediated via β-adrenergic mechanisms (1982) (1)
Letter: Potentiation of antidepressant action of clomipramine by tryptophan. (1975) (1)
1227 – NALOXONE BLOCKADE OF THE SUBSTANCE P-INDUCED DOPA FORMATION IN RAT BRAIN (1978) (1)
The efficacy of the partial dopamine agonist (-)-3PPP in schizophrenia (1994) (1)
Effect of desipramine and reserpine on the in vivo beta-hydroxylation of alpha-methyl-m-tyramine and alpha-methyldopamine. (1967) (0)
Open‐label study with the monoamine stabilizer (‐)‐OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome (2021) (0)
Exosomes and Exosomal RNA (2012) (0)
Genetic diseases and disorders in dogs (1989) (0)
Oral Health in Swedish Women (2015) (0)
Neurotransmitter Interactions Important for Schizophrenia (1996) (0)
THIS MONTH IN ARCHIVES OF GENERAL PSYCHIATRY This Month in Archives of General Psychiatry PERSPECTIVES (2005) (0)
18. Marts Hjärnans monoaminer (1966) (0)
SAHLGRENSKA AKADEMIN On the Origins of mobile Antibiotic Resistance Genes A comparative genomics approach (2021) (0)
Seasonal and circadian monoamine variations in human brains examined post mortem. (1980) (0)
A methodological platform to study molecular biocompatibility of biomaterials Experimental and clinical studies (2016) (0)
ON THE ROLE OF CATECHOL‐O‐METHYL TRANSFERASE IN BRAIN (1962) (0)
Searching for antemortem markers premature (1986) (0)
SAHLGRENSKA AKADEMIN INSTITUTIONEN FÖR ODONTOLOGI Preclinical Studies for Cryoprevention of Oral Mucositis (2019) (0)
Substituted (S) -3-phenylpiperidine derivatives, antagonists, their preparation and their use as a dopamine autoreceptor (1992) (0)
Effects of Pharmacological Manipulations of 5-ht2a and Glycine Receptors in a Mouse Model of Hypoglutamatergia (1996) (0)
The Parkinson's Journey: From Drug Discovery to Treatment of Early and Advancing Disease (2014) (0)
79 Biochemical heterogeneity in schizophrenia due to gender: A multivariate study of post-mortem brain biochemistry (1997) (0)
Author response for "Open‐label study with the monoamine stabilizer (‐)‐OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome" (2020) (0)
A Paradigm Shift in Brain Research (1955–1970): Opportunities and ChallengesSeventy Years of Brain Research — Looking Back and Ahead (2019) (0)
Enantiomers of 3-(3,4-Dihydroxyphenyl)- and 3-(3-Hydroxyphenyl)-N-n- propylpiperidine: Central Pre- and Postsynaptic Dopaminergic Effects and Pharmacokinetics. (1987) (0)
SAHLGRENSKA AKADEMIN TO PREDICT RESULTS OF BREAST CANCER THERAPY (2019) (0)
The Role of the Autonomic Nervous System in Atherosclerosis (2017) (0)
DIFFERENTIAL LOCOMOTOR INTERACTIONS BETWEEN DOPAMINE D1/D2 RECEPTOR AGONISTS AND THE NMDA ANTAGONIST MK‐801 IN MONOAMINE‐DEPLETED MICE (1992) (0)
Staining and chemo-mechanical excavation (2017) (0)
SAHLGRENSKA AKADEMIN Early Stage Inflammation and Cancer as Reflected in the Gastrointestinal Mucus Composition (2018) (0)
The role of physical activity for recovery after surgical procedures (2021) (0)
Overview of Dopamine Systems and Schizophrenia (2003) (0)
Potentiation of the effect of antidepressant drugs by tryptophan. (1980) (0)
Signal Transduction In The Nervous System 2000 (2018) (0)
Reflections on the history of psychopharmacology. (1988) (0)
S-32-3 Brain biochemistry in the normal and hypoglutamatergic state — What distinguishes atypical from typical antipsychotics? A multivariate approach (1996) (0)
Cost-Effectiveness of Vaccination and the Value of Prevention (2020) (0)
MONOPHENOLIC 2-(DIPROPYLAMINO)INDANS AND RELATED COMPOUNDS: CENTRAL DOPAMINE-RECEPTOR STIMULATING ACTIVITY (1981) (0)
Transport of biological amines as an element of drug action (2005) (0)
Reply to the editor (2001) (0)
Receptor research: a challenge for drug development (1993) (0)
Pathophysiology and treatment of Takotsubo Syndrome (2020) (0)
Interactions between central glutamatergic, catecholaminergic and cholinergic systems with regard to locomotor activity in monoamine-depleted mice (1992) (0)
Adrenergic Influence on Plasma and Brain Concentrations of Phenylalanine and Other Large Neutral Amino Acids in Rats (1988) (0)
P.6.b.009 Effect of the monoamine stabilizer (-)-OSU6162 on cognitive function in alcohol dependent patients (2017) (0)
Brief Report: Preclamol and Parkinsonian Fluctuations (1993) (0)
Pharmacology of Reserpine Analogues VI. Reserpine Analogues with Differential Effect on Brain Monoamines (2009) (0)
Towards a new understanding of dopamine receptors. Discussion (1995) (0)
Neurobiological Aspects of Psychiatric Consequences of Physical Illness (1989) (0)
BIOCHEMISTRY AND PHYSIOLOGY OF BRAIN DOPAMINE (1965) (0)
SY12TREATMENT TARGETS TO REDUCE CRAVING AND ALCOHOL INTAKE IN ALCOHOL ADDICTION: FROM BENCH TO BEDSIDESY12-1THE MONOAMINE STABILISER (-)-OSU6162 - A POTENTIAL NOVEL TREATMENT OF ALCOHOL USE DISORDERS: ANIMAL AND HUMAN STUDIES (2015) (0)
The Dopamine Hypothesis of Schizophrenia: New Aspects (2002) (0)
ADRENAL MEDULLA ‐ SOME ASPECTS OF POSSIBLE IMPORTANCE FOR ADRENAL‐BRAIN TRANSPLANTATION (1992) (0)
NEUROTRANSMITTERS AND RELATED ENZYMES IN NORMAL AGING AND SENILE DEMENTIA (1980) (0)
Formation of dopamine from 3-methoxytyrosine. Fact or artifact? (1972) (0)
BASAL GANGLIA GLUTAMATE TRANSMISSION AND PSYCHOMOTOR FUNCTIONS (1992) (0)
On the catechol amine levels in blood plasma after stimulation of the sympathoadrenal system (2005) (0)
I. c. v. dopamine fails to alter adrenomedullary function in rats (2005) (0)
The role of animal experiments in pharmacological brain research (1990) (0)
The aging brain and its disorders (1990) (0)
Proceedings: Short-term control of tyrosine hydroxylase. (1974) (0)
Studies on the Etiology of Parkinson’s disease (2020) (0)
Release of α‐Methylated Noradrenaline Analogues by Nialamide (2009) (0)
EFFECT OF DIAZEPAM ON BRAIN MONOAMINE METABOLISM (1979) (0)
SAHLGRENSKA AKADEMIN Aspects of Communication, Language and Literacy in Autism (2019) (0)
Interactions between Glutamate and Dopamine in the Ventral Striatum: Evidence for a Dual Glutamatergic Function with Respect to Motor Control (1995) (0)
BIOCHEMISTRY AND PHYSIOLOGY OF DOPAMINE IN THE BRAIN. (1969) (0)
Synapses , sea slugs , and psychiatry (2000) (0)
The prospects of new antipsychotic principles (1997) (0)
Resolved 2-Arylcyclohexylamines: Effects on Reserpine Akinesia and Central Nervous System Monoamine Synthesis. (1993) (0)
A study of the contribution of mast cells to vaccination-Regulatory functions of Fcγ receptors (2013) (0)
On the beta-hydroxylation of (+-)-alpha-methyldopamine in vivo. (1968) (0)
Febrile seizures and associated neurodevelopmental disorders (2020) (0)
292 – EFFECT OF INTRACEREBROVENTRICULARLY ADMINISTERED CYCLIC NUCLEOTIDES ON BRAIN MONOAMINE METABOLISM AND EVIDENCE FOR THEIR INVOLVEMENT IN PRESYNAPTIC DOPAMINERGIC ACTIVITY (1978) (0)
Synthesis and Biological Activity of cis-(3aR)-(-)-2,3,3a,4,5,9b- Hexahydro-3-propyl-1H-benz(e)indole-9-carboxami de (VII): A Potent and Selective 5-HT1A Receptor Agonist with Good Oral Availability. (1994) (0)
Eosinophils , their progenitors and T helper cells in allergic airway inflammation (2011) (0)
Childhood BMI and Pubertal Timing Changes over time and associations with adult cardiovascular mortality (2019) (0)
α-Methyl-p-tyrosine Induced Disappearance of Dopamine in Substantia Nigra: Effect of Apomorphine, Haloperidol and GBL (1986) (0)
The 12th Congress — Gothenburg 1980 (1988) (0)
Release of alpha-methylated noradrenaline analogues by nialamide. (1968) (0)
218 Effects of antipsychotics on brain biochemistry in the normal and hypoglutamatergic state-identification of antipsychotic mechanisms: A multivariate approach (1997) (0)
3-PHENYLPIPERIDINES. CENTRAL DOPAMINE-AUTORECEPTOR STIMULATING ACTIVITY (1982) (0)
Adrenal medulla as a target for dopaminergic drugs (1993) (0)
Transcriptomic and functional studies of fusion oncogene-driven salivary gland tumors (2020) (0)
On the catehol amine in blood plasma after stimulation of the sympathoadrenal system. (1958) (0)
Regulation of catecholamine turnover : proceedings of a conference held in Göteborg, Sweden, July 17-19, 1975 (1975) (0)
DA stabilisers — fourth generation antipsychotic drugs (2003) (0)
587 The treatment of schizophrenia with partial dopamine agonist: A promising strategy (1997) (0)
Additions and Corrections-Enantiomers of 3-(3,4-Dihydroxyphenyl)- and 3-(3-Hydroxyphenyl)-N-n-propylpiperdine: Central Pre- and Postsynaptic Dopaminergic Effects and Pharmacokinetics (1987) (0)
Animal data in support of the treatment of EPS with partial dopamine receptor agonists (1993) (0)
[Theories on the models of action of antipsychotic drugs]. (1973) (0)
Potentiering Av Neuroleptika Med Synteshämmaren α-Metyltyrosin Vid Behandling Av Kronisk Schizofreni (1973) (0)
CURRENT TRENDS IN PHARMACOTHERAPY BASED ON MONOAMINERGIC MECHANISMS (1978) (0)
Neuroscience news (2000) (0)
Fatigue in persons with rheumatoid arthritis (2015) (0)
mechanism ofcentral andperipheral monoamine neurones invivoandinvitro (1969) (0)
Trackers of the Slow Synaptic Phenomena in the Brain (2013) (0)
1540 – CATECHOLAMINE INVOLVEMENT IN THE DISRUPTION OF THE CONDITIONED AVOIDANCE RESPONSE UNDER HYPOXIA (1977) (0)
Regioselective Synthesis of 3‐Aryl Substituted Pyrrolidines via Palladium Catalyzed Arylation: Pharmacological Evaluation for Central Dopaminergic and Serotonergic Activity. (1997) (0)
A Paradigm Shift in Brain Research (1955-1970): Opportunities and Challenges: Seventy Years of Brain Research - Looking Back and Ahead (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Arvid Carlsson?

Arvid Carlsson is affiliated with the following schools:

University of Gothenburg

Arvid Carlsson's Academic­Influence.com Rankings

Why Is Arvid Carlsson Influential?

Arvid Carlsson's Published Works

Published Works

What Schools Are Affiliated With Arvid Carlsson?

Arvid Carlsson's AcademicInfluence.com Rankings